What Is The Worst Virus In The World?
Breast cancer is a common female disease,and the most common population is middle-aged women. In China, breast cancerranks the top two among female malignant tumors. Worldwide, about 1.2 millionwomen develop breast cancer every year, and 500,000 women die from breastcancer. The main treatment methods for breast cancer include surgical removalof the ovaries, radiotherapy of both ovaries, and drug therapy. As the level ofbreast cancer treatment continues to improve, more and more therapeutic drugshave surfaced. These drugs generally reduce the level of estrogen in the bodyto achieve the effect of treating breast cancer. The relevant information onthe Internet has compiled top 10 most common drugs for the treatment of breastcancer in recent years. The following are the top 10 most common drugs to treatbreast cancer.
1. Furui: It is a new generation ofaromatase inhibitors, and aromatase inhibitors are generally well tolerated.However, adverse reactions such as gastrointestinal disturbances, weakness,headache, hot flashes, and musculoskeletal pain are often seen.
2. Everolimus: Everolimus is amultifunctional mammalian target of rapamycin (mTOR) inhibitor, and mTOR is anintracellular serine/threonine kinase and is an intracellular centralregulator. Changes in intracellular growth factors and nutrient energy signalscan be sensed.
3. Paclitaxel injection: Paclitaxel hasbeen approved by the FDA for the adjuvant treatment of advanced breast cancer,and can also be used for the treatment of patients who have failed combinedchemotherapy or have relapsed within 6 months of adjuvant therapy. Commonadverse effects of paclitaxel are myelosuppression, myalgia, arthralgia,mucositis, nausea and vomiting, as well as alopecia and peripheral nervedamage.
4. Epothilone B: a new type of microtubulestabilizer, which has the effect of promoting GTP-dependent tubulinpolymerization to form microtubules, and has a stabilizing effect onmicrotubules; and inhibits microtubules by stabilizing the assembly process ofmicrotubules. Depolymerization leads to abnormal arrangement of microtubulebundles and the formation of stellate, which in turn inhibits the formation ofnormal mitotic spindles by cells, thereby inhibiting the growth of tumor cellsand even inducing their death.
5. Herceptin: It is a recombinantDNA-derived humanized monoclonal antibody. Its single-drug efficacy is similarto that of chemotherapy drugs, but there will be no adverse reactions such ashair loss, mucositis, and hematological toxicity caused by chemotherapy drugs.The patients were well tolerated.
6. Xeloda: It is a new generation of oralfluoropyrimidine drugs, which can be rapidly absorbed in the form of theoriginal drug in the gastrointestinal tract and metabolized into anti-tumoractive substances in the liver and tumor tissue. It is currently approved inseveral countries for patients with advanced breast cancer who have failedtaxane and anthracycline therapy.
7. Apatinib: Apatinib is chemically namedmesylate N-[4-(cyano-cyclopentyl) phenyl]{2-[(4-pyridine methyl)amino](3-pyridine)} formamide, a small molecule VEGFR2 inhibitor that mainlyinhibits VEGFR2 activity and also inhibits VEGFR1 and RET.
8. Sulai: The growth of breast cancer cellsdepends on the presence of estrogen. The estrogen in the postmenopausal women'scirculation is mainly converted from androgens in the adrenal gland, liver,muscle and fat by aromatase in peripheral tissues. Therefore, blocking estrogenproduction by inhibiting aromatase is an effective and selective method for thetreatment of hormone-dependent breast cancer in postmenopausal women. The drugsignificantly reduces circulating estrogen levels in postmenopausal women, buthas no significant effect on corticosteroid biosynthesis in the adrenal glands.
9. Cipatinib: Cipatinib is a small moleculemulti-target, 4-anilinoquinazoline receptor tyrosine kinase inhibitor, whichinhibits epidermal growth factor receptor (ErbB1/EGFR) and human epidermalfactor Receptor 2 (ErbB2/HER-2).
10. Anti-estrogen drugs: These are the mostcommonly used non-steroidal anti-estrogen drugs, which can bind to estrogenreceptors and block the effect of estrogen on the receptors. The most commonlyused is tamoxifen (TAM), which can be used for rescue treatment of recurrentand metastatic breast cancer, postoperative adjuvant treatment and preventionof breast cancer in high-risk healthy women.
Overall, the above top 10 most common drugsfor breast cancer are both affordable and effective, and these top 10 mostcommon drugs to treat breast cancer are necessary for families with breastcancer patients. The process of tumor treatment is full of ups and downs, butwith the continuous deepening of research and the continuous launch of newdrugs, the treatment of breast cancer will gradually achieve individualizationand precision, and one day tumors will become chronic diseases.
Looking for chemical products? Let suppliers reach out to you!
2026-09-29
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Breath Test Lung Cancer Screening In China
-
Reduced the Risk of Disease Progression by 71% Innovative Anti-cancer Therapy Reached Phase 3 Clinical Endpoint
-
Sulfuric Acid Reactions: With Sugar (Dehydration), Water, and Metals
-
What is Serine? (Amino Acid Function & Sources)
-
Chemical Reactions and Uses of Stilbene
-
Uses of Dithiothreitol in Laboratories
-
Chemical Properties of Dibenzylideneacetone
-
Applications of Diphenyl Cyanide
-
EFSA Reviews Clodinafop Risk
-
ADAMA Targets Sucking Pests with Ateka
Recommend Reading
-
Hydrogen Peroxide Formula: H2O2 Concentration & Safety
-
Imidazole: Heterocyclic Chemistry, Antifungal Drugs, and Buffer Systems
-
Salinity Solution: Preparation and Uses
-
Understanding Titanium Oxide: Properties and Uses
-
Rubber Cement: Applications and Safety Guidelines
-
Business Society’s Market Outlook for Epichlorohydrin on August 24, 2026: Price Trend Is Expected to Be Volatile
-
Bearish Factors Dominate, Adipic Acid Prices Decline
-
Cost Decline, Weak Demand: October Phthalic Anhydride Prices Continue to Fall
-
This week, the styrene market in China showed a strong upward trend (7.6-7.10)
-
Business Society’s Phenol Trend Analysis for September 15, 2026: Slight Decline